Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163740 | 0.85 | MAPT (0.40) | MAPTHPGDKMT2AL3MBTL1TDP1 | |
| SCHEMBL6979862 | 0.82 | TP53 (0.40) | MAPTHPGDL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL2142085 | 0.81 | DUT (0.35) | MAPTHPGDKMT2AALDH1A1MEN1 | |
| SCHEMBL1246103 | 0.81 | DUT (0.35) | DUT | |
| SCHEMBL24197440 | 0.78 | DUT (0.38) | DUT | |
| SCHEMBL2139606 | 0.78 | DUT (0.35) | DUT | |
| SCHEMBL4738386 | 0.77 | DUT (0.35) | MAPTHPGDTDP1ALDH1A1HSD17B10 | |
| SCHEMBL1247752 | 0.75 | DUT (0.35) | KMT2AALDH1A1DUT | |
| SCHEMBL20764835 | 0.75 | KDM4E (0.35) | MAPTKMT2AL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL12970675 | 0.75 | DUT (0.35) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077385-B1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-10-04 | — | — | EP | disclosed |
| EP-3077385-B1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-10-04 | — | — | EP | disclosed |
| EP-3077385-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | Chiesi Farmaceutici S.p.A. (IT) | 2016-10-12 | — | — | EP | disclosed |
| US-9133185-B2 | Heteroaryl derivatives | CHIESI FARMACEUTICI S.P.A (IT) | 2015-09-15 | — | — | US | disclosed |
| US-9133185-B2 | Heteroaryl derivatives | CHIESI FARMACEUTICI S.P.A (IT) | 2015-09-15 | — | — | US | disclosed |
| US-9133185-B2 | Heteroaryl derivatives | CHIESI FARMACEUTICI S.P.A (IT) | 2015-09-15 | — | — | US | disclosed |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082616-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015082616-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158858-A1 | HETEROARYL DERIVATIVES | PDE4A, PDE4B, PDE3A | MAPT 4726/4885HPGD 356/4885KMT2A 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.